Your session is about to expire
← Back to Search
BIXINK OC Free for Obsessive-Compulsive Disorder
N/A
Recruiting
Led By Eric Hollander, MD
Research Sponsored by BIXINK Therapeutics Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up endpoint (week 6), follow-up (week 10)
Awards & highlights
No Placebo-Only Group
Summary
This trial tests an app called OC Free that helps adults with severe contamination OCD practice their therapy exercises at home. The app uses a method to help them face their fears and reduce compulsive behaviors. The study will check if the app is safe and effective over several weeks. This method is a well-established treatment for OCD, known for its effectiveness in reducing symptoms.
Eligible Conditions
- Obsessive-Compulsive Disorder
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ endpoint (week 6), follow-up (week 10)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~endpoint (week 6), follow-up (week 10)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Yale-Brown Obsessive-Compulsive Scale (Y-BOCs)
Secondary study objectives
Beck Anxiety Inventory
Mental Depression
Clinical Global Impression - Improvement scale (CGI-I)
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: BIXINK OC FreeExperimental Treatment1 Intervention
A 6 week ERP-based intervention
Find a Location
Who is running the clinical trial?
BIXINK Therapeutics Co., Ltd.Lead Sponsor
Eric Hollander, MDPrincipal InvestigatorSpectrum Neuroscience and Treatment Institute
16 Previous Clinical Trials
619 Total Patients Enrolled
2 Trials studying Obsessive-Compulsive Disorder
187 Patients Enrolled for Obsessive-Compulsive Disorder
Share this study with friends
Copy Link
Messenger